Theratechnologies Inc. (TH) - Total Assets
Based on the latest financial reports, Theratechnologies Inc. (TH) holds total assets worth CA$51.27 Million CAD (≈ $37.09 Million USD) as of May 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Theratechnologies Inc. cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Theratechnologies Inc. - Total Assets Trend (1996–2024)
This chart illustrates how Theratechnologies Inc.'s total assets have evolved over time, based on quarterly financial data. Explore Theratechnologies Inc. long-term investment intensity to see how much of total assets are deployed in long-term investments.
Theratechnologies Inc. - Asset Composition Analysis
Current Asset Composition (November 2024)
Theratechnologies Inc.'s total assets of CA$51.27 Million consist of 82.5% current assets and 17.6% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$3.72 Million | 11.1% |
| Accounts Receivable | CA$14.97 Million | 28.1% |
| Inventory | CA$5.28 Million | 9.9% |
| Property, Plant & Equipment | CA$1.26 Million | 2.4% |
| Intangible Assets | CA$7.57 Million | 14.2% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Theratechnologies Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Theratechnologies Inc. (TH) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theratechnologies Inc.'s current assets represent 82.5% of total assets in 2024, an increase from 81.7% in 1996.
- Cash Position: Cash and equivalents constituted 11.1% of total assets in 2024, down from 46.6% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 28.1% of total assets.
Theratechnologies Inc. Competitors by Total Assets
Key competitors of Theratechnologies Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Theratechnologies Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.84 | 1.10 | 1.90 |
| Quick Ratio | 0.65 | 1.00 | 1.14 |
| Cash Ratio | 0.01 | 0.00 | 0.00 |
| Working Capital | CA$-6.15 Million | CA$5.34 Million | CA$30.29 Million |
Theratechnologies Inc. - Advanced Valuation Insights
This section examines the relationship between Theratechnologies Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.46 |
| Latest Market Cap to Assets Ratio | 2.79 |
| Asset Growth Rate (YoY) | -31.4% |
| Total Assets | CA$53.34 Million |
| Market Capitalization | $148.68 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Theratechnologies Inc.'s assets at a significant premium (2.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Theratechnologies Inc.'s assets decreased by 31.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Theratechnologies Inc. (1996–2024)
The table below shows the annual total assets of Theratechnologies Inc. from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-11-30 | CA$53.34 Million ≈ $38.59 Million |
-31.41% |
| 2023-11-30 | CA$77.77 Million ≈ $56.26 Million |
-16.61% |
| 2022-11-30 | CA$93.26 Million ≈ $67.46 Million |
-21.77% |
| 2021-11-30 | CA$119.21 Million ≈ $86.24 Million |
+19.04% |
| 2020-11-30 | CA$100.14 Million ≈ $72.44 Million |
-14.81% |
| 2019-11-30 | CA$117.56 Million ≈ $85.04 Million |
+5.66% |
| 2018-11-30 | CA$111.25 Million ≈ $80.48 Million |
+87.65% |
| 2017-11-30 | CA$59.29 Million ≈ $42.89 Million |
+50.36% |
| 2016-11-30 | CA$39.43 Million ≈ $28.52 Million |
+5.27% |
| 2015-11-30 | CA$37.46 Million ≈ $27.10 Million |
+31.39% |
| 2014-11-30 | CA$28.51 Million ≈ $20.62 Million |
+21.82% |
| 2013-11-30 | CA$23.40 Million ≈ $16.93 Million |
-36.02% |
| 2012-11-30 | CA$36.58 Million ≈ $26.46 Million |
-28.57% |
| 2011-11-30 | CA$51.20 Million ≈ $37.04 Million |
-27.14% |
| 2010-11-30 | CA$70.28 Million ≈ $50.84 Million |
+6.98% |
| 2009-11-30 | CA$65.70 Million ≈ $47.52 Million |
+50.69% |
| 2008-11-30 | CA$43.60 Million ≈ $31.54 Million |
-41.52% |
| 2007-11-30 | CA$74.55 Million ≈ $53.93 Million |
+66.97% |
| 2006-11-30 | CA$44.65 Million ≈ $32.30 Million |
-2.79% |
| 2005-11-30 | CA$45.93 Million ≈ $33.23 Million |
-19.74% |
| 2004-11-30 | CA$57.23 Million ≈ $41.40 Million |
-21.47% |
| 2003-11-30 | CA$72.88 Million ≈ $52.72 Million |
-18.83% |
| 2002-11-30 | CA$89.78 Million ≈ $64.95 Million |
-0.66% |
| 2001-11-30 | CA$90.38 Million ≈ $65.38 Million |
+64.34% |
| 2000-11-30 | CA$54.99 Million ≈ $39.78 Million |
+198.81% |
| 1999-11-30 | CA$18.40 Million ≈ $13.31 Million |
+48.00% |
| 1998-11-30 | CA$12.43 Million ≈ $9.00 Million |
+46.24% |
| 1997-11-30 | CA$8.50 Million ≈ $6.15 Million |
-47.68% |
| 1996-11-30 | CA$16.25 Million ≈ $11.76 Million |
-- |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more